Upcoming diagnostic biomarkers with promising prospects in neurological disorders.
network approach
neurodiagnostic marker specific neurodiagnostic biomarker
neurological disorders
non-specific neurodiagnostic biomarker
personalized medication
Journal
Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
08
05
2019
revised:
09
09
2019
accepted:
16
11
2019
pubmed:
21
11
2019
medline:
8
5
2021
entrez:
21
11
2019
Statut:
ppublish
Résumé
An exponential increase in the prevalence of neurological disorders requires substantial steps to be taken for their prevention and treatment. Neurodiagnostic biomarkers are gaining momentum presently in order to enhance the diagnostic accuracy of neurodegenerative disorders, to precisely assess their advancement and to monitor the efficiency of therapeutic interventions. Therefore, the primary focus of the present review is the recent development in this field of neurodiagnostic biomarkers, and the current state of biomarker exploration in the context of various neurodegenerative diseases. This review encompasses an updated and detailed account of specific (β-Amyloid, Tau and Phospho-tau 181, Tar-DNA binding protein-43, Progranulin, a-synuclein, Clusterin, etc) and non-specific (genetic, synaptic, inflammatory and coagulation) neurodiagnostic biomarkers and the recent advances in this growing field. This comprehensive review also suggests the utilization of neurodiagnostic markers in network approaches and personalized medication that will eventually improvise the existing diagnostic and therapeutic complexities of neurodiagnostic biomarkers.
Identifiants
pubmed: 31746003
doi: 10.1111/1440-1681.13216
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
GRN protein, human
0
Genetic Markers
0
MAPT protein, human
0
Progranulins
0
tau Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-356Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.
Références
Feigin VL, Abajobir AA, Abate KH, et al. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877-897.
Husain I, Khan S, Khan S, Madaan T, Kumar S, Najmi AK. Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders. Clin Exp Pharmacol Physiol. 2019;46:283-291.
Lashley T, Holton JL, Gray E, et al. Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008;115:417-425.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614-629.
Chen G, Xu T, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38:1205-1235.
Seppälä T, Nerg O, Koivisto A, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012;78:1568-1575.
Moghekar A, Li S, Lu Y, et al. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology. 2013;81:1753-1758.
Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385-393.
Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature. 2018;554:249.
Medina M, Hernández F, Avila J. New features about tau function and dysfunction. Biomolecules. 2016;6:21.
Melková K, Zapletal V, Narasimhan S, et al. Structure and functions of microtubule associated proteins tau and MAP2c: similarities and differences. Biomolecules. 2019;9:105.
Sjögren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70:624-630.
Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 2007;419:18-22.
Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegener. 2017;12:63.
French RL, Grese ZR, Aligireddy H, et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. JBC. 2019;294:6696-6709.
Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65:1481-1487.
Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018;1-13.
Kasai T, Tokuda T, Ishigami N, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55-62.
Suárez-Calvet M, Dols-Icardo O, Lladó A, et al. Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry. 2014;85:684-691.
Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain. 2017;140(12):3081-3104.
Schofield EC, Halliday GM, Kwok J, Loy C, Double KL, Hodges JR. Low serum progranulin predicts the presence of mutations: a prospective study. J Alzheimers Dis. 2010;22:981-984.
Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235-1239.
Sleegers K, Brouwers N, Van Damme P, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603-609.
Kao AW, McKay A, Singh PP, Brunet A, Huang EJ. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci. 2017;18:325.
Yuan A, Rao MV, Veeranna NRA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2017;9:a018309.
Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116-126.
Waldö ML, Santillo AF, Passant U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol. 2013;13:54.
Steinacker P, Semler E, Anderl-Straub S, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017;88:961-969.
Emamzadeh FN. Alpha-synuclein structure, functions, and interactions. J Res Med Sci. 2016;21:29.
Stefanis L. α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009399.
Colom-Cadena M, Pegueroles J, Herrmann AG, et al. Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain. 2017;140:3204-3214.
Wu Z-C, Yu J-T, Li Y, Tan L. Clusterin in Alzheimer's disease. Adv Clin Chem. 2012;56:155.
Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer's disease: mechanisms, genetics, and lessons from other pathologies. Front Neurosci. 2019;13:164.
Miners S, Clarke P, Love S. clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ: o09. Neuropathol Appl Neurobiol. 2016;42:15-16.
Husain I, Akhtar M, Madaan T, et al. Tannins enriched fraction of emblica officinalis fruits alleviates high-salt and cholesterol diet-induced cognitive impairment in rats via Nrf2-ARE pathway. Front Pharmacol. 2018;9:23.
Li H, Wang X, Yu H, et al. Combining in vitro and in silico approaches to find new candidate drugs targeting the pathological proteins related to the Alzheimer's disease. Curr Neuropharmacol. 2018;16:758-768.
Nordestgaard LT, Tybjaerg-Hansen A, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R. Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals. BMC Med. 2018;16:39.
Rajagopalan P, Refsum H, Hua X, et al. Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. Neurobiol Aging. 2013;34(4):1221-1230.
Duits FH, Brinkmalm G, Teunissen CE, et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Res Ther. 2018;10:5.
Guoxiang H, Hui L, Yong Z, Xunming J, Zhuo C. Association between cystatin C and SVD in Chinese population. Neurol Sci. 2018;1-6.
Lee W-J, Jung K-H, Ryu YJ, et al. Cystatin C, a potential marker for cerebral microvascular compliance, is associated with white-matter hyperintensities progression. PLoS ONE. 2017;12:e0184999.
Goyal A, Failla MD, Niyonkuru C, et al. S100b as a prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma. 2013;30:946-957.
Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:d1356-d1368.
Thelin EP, Nelson DW, Bellander B-M. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir. 2017;159:209-225.
Anderson RE, Hansson L-O, Nilsson O, Dijlai-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;48:1255-1260.
Koh SX, Lee JK. S100B as a marker for brain damage and blood-brain barrier disruption following exercise. Sports Med. 2014;44:369-385.
Bishop P, Rocca D, Henley JM. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem J. 2016;473(16):2453-2462.
Butterfield DA, Boyd-Kimball D. Redox proteomics and amyloid β-peptide: insights into Alzheimer disease. J Neurochem. 2018;151(4):459-487.
Liu MC, Akinyi L, Scharf D, et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci. 2010;31:722-732.
Puvenna V, Brennan C, Shaw G, et al. Significance of ubiquitin carboxy-terminal hydrolase L1 elevations in athletes after sub-concussive head hits. PLoS ONE. 2014;9:e96296.
Haque A, Ray SK, Cox A, Banik NL. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. Metab Brain Dis. 2016;31:487-495.
Polcyn R, Capone M, Hossain A, Matzelle D, Banik NL, Haque A. Neuron specific enolase is a potential target for regulating neuronal cell survival and death: implications in neurodegeneration and regeneration. Neuroimmunol Neuroinflamm. 2017;4:254-257.
Isgrò MA, Bottoni P, Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:125-143.
Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4-12.
Guzel A, Er U, Tatli M, et al. Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with Glasgow Coma Scale in traumatic brain injury. Neurosurg Rev. 2008;31:439.
Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Sanae MM. Iguchi-Ariga, “Neuroprotective function of DJ-1 in Parkinson's disease”. Oxid Med Cell Longev. 2013;2013:683920.
Saito Y. DJ-1 as a biomarker of Parkinson's disease. Adv Exp Med Biol. 2017;1158:149-171.
Allard L, Burkhard PR, Lescuyer P, et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 2005;51:2043-2051.
Agrawal M, Biswas A. Molecular diagnostics of neurodegenerative disorders. Front Mol Biosci. 2015;2:54.
Lachenal G, Pernet-Gallay K, Chivet M, et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci. 2011;46:409-418.
Soreq L, Salomonis N, Bronstein M, et al. Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Biosci. 2013;6:10.
Lin J, Li J, Huang B, et al. Exosomes: novel biomarkers for clinical diagnosis. ScientificWorldJournal. 2015;2015:657086.
Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72:1275-1280.
Husain I, Akhtar M, Shaharyar M, et al. High-salt- and cholesterol diet-associated cognitive impairment attenuated by tannins-enriched fraction of Emblica officinalis via inhibiting NF-kB pathway. Inflammopharmacology. 2018;26:147-156.
Skaper SD, Facci L, Zusso M, An GP. Inflammation-centric view of neurological disease: beyond the neuron. Front Cell Neurosci. 2018;12:72.
Zhang S, Wang XJ, Tian LP, et al. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflammation. 2011;8:154.
Rangasamy SB, Corbett GT, Roy A, et al. Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease. J Alzheimer's Dis. 2015;47:385-402.
Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011;12:695-708.
Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging. 2015;36:608-617.
Walsh AC. Anticoagulant therapy for Alzheimer's disease. J Neuropsy Clin Neurosci. 1996;8:361-362.
Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels. Neurobiol Dis. 2010;40:340-347.
Santiago JA, Bottero V, Potashkin JA. Dissecting the molecular mechanisms of neurodegenerative diseases through network biology. Front Aging Neurosci. 2017;9:166.
Polivka J, Polivka J Jr, Krakorova K, Peterka M, Topolcan O. Current status of biomarker research in neurology. EPMA J. 2016;7:14.
Mandel SA, Morelli M, Halperin I, Korczyn AD. Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J. 2010;1:273-292.